Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
European Commission
About
Opens for applications on 2027-02-10. A European Commission call for proposals. Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities; Researchers, physicians, innovators [1] , startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation; National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems; Scope: Patients with rare and very rare [2] cancers across EU Member State
Who can apply
Usually organisations in EU member states and associated countries, often in a consortium. Some calls are open to partners from other countries. Check the call conditions.
Best for
- Researchers
- NGOs
- Founders
- Location
- Europe
- Cost
- Free to apply
- Organizer
- European Commission
- 43108390
- eu funding